BioRestorative completes enrollment for safety run-in of Phase 2 BRTX-100 study
The Fly

BioRestorative completes enrollment for safety run-in of Phase 2 BRTX-100 study

BioRestorative Therapies announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting patients suffering from chronic lumbar disc disease. BRTX-100 is the Company’s lead clinical candidate, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial to treat cLDD. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug or control in a 2:1 fashion.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BRTX:

Related Articles
TipRanks Auto-Generated NewsdeskBioRestorative Therapies Clarifies Press Release Usage in Filings
Ryan AdistBRTX Upcoming Earnings Report: What to Expect?
TipRanks Auto-Generated NewsdeskBioRestorative Therapies Issues Financial Update Notice
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App